• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters1
Displaying 54-68 of 759 results

No. 23 ORDER Directing the Parties shall file supplementary briefs, and shall be no longer than (3) ...

Document TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. et al v. DEVA HOLDING A.S., 2:24-cv-04404, No. 23 (D.N.J. Aug. 5, 2024)
This matter comes before the Court on the motion to dismiss by Defendant Deva Holding A.S.
The statute, 35 U.S.C. § 271(e) (emphasis added), states: (2) It shall be an act of infringement to submit— (A) an application under section 505(j) of the Federal Food, Drug, and Cosmetic Act [21 USCS § 355(j)] or described in section 505(b)(2) of such Act [21 USCS § 355(b)(2)] for a drug claimed in a patent or the use of which is claimed in a patent ...
The parties shall file supplementary briefs on this question: what is the definition of “drug” in the context of this statutory provision?
Briefs shall be no longer than three pages and shall be submitted simultaneously by August 19, 2024.
cite Cite Document
Analyze

No. 49 OPINION

Document EBIN NEW YORK, INC. v. KISS NAIL PRODUCTS, INC. et al, 2:23-cv-02369, No. 49 (D.N.J. Mar. 28, 2024)
Log in to see more
cite Cite Document
Analyze

No. 252 OPINION AND ORDER

Document GW RESEARCH LIMITED v. TEVA PHARMACEUTICALS, INC. et al, 2:23-cv-00018, No. 252 (D.N.J. Jan. 11, 2024)
Log in to see more
cite Cite Document
Analyze

No. 73 OPINION AND ORDER

Document NOVAPLAST CORPORATION v. INPLANT, LLC et al, 2:20-cv-07396, No. 73 (D.N.J. Jul. 26, 2023)
Log in to see more
cite Cite Document
Analyze

No. 24 CONSENT ORDER EXTENDING TIME TO ANSWER through 7/21/2023; vacating 2/2/2023 entry of default

Document DAYS INNS WORLDWIDE, INC. v. AVST HOSPITALITY, LLC et al, 2:22-cv-01935, No. 24 (D.N.J. Jul. 10, 2023)
Log in to see more
cite Cite Document
Analyze

No. 1

Document CURELIFE CO., LTD. et al v. IDEAVILLAGE PRODUCTS CORP., 2:24-cv-10910, No. 1 (D.N.J. Dec. 4, 2024)

cite Cite Document
Analyze

No. 126

Document INCYTE CORPORATION et al v. SUN PHARMACEUTICAL INDUSTRIES LTD. et al, 2:24-cv-06944, No. 126 (D.N.J. Oct. 22, 2024)

cite Cite Document
Analyze

No. 37

Document TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. et al v. DEVA HOLDING A.S., 2:24-cv-04404, No. 37 (D.N.J. Sep. 18, 2024)

cite Cite Document
Analyze

No. 36

Document TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. et al v. DEVA HOLDING A.S., 2:24-cv-04404, No. 36 (D.N.J. Sep. 11, 2024)

cite Cite Document
Analyze

No. 25

Document TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. et al v. DEVA HOLDING A.S., 2:24-cv-04404, No. 25 (D.N.J. Aug. 19, 2024)

cite Cite Document
Analyze

No. 60

Document TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. et al v. DEVA HOLDING A.S., 2:24-cv-04404, No. 60 (D.N.J. Mar. 6, 2025)

cite Cite Document
Analyze

No. 58

Document TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. et al v. DEVA HOLDING A.S., 2:24-cv-04404, No. 58 (D.N.J. Mar. 5, 2025)

cite Cite Document
Analyze

No. 57

Document TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. et al v. DEVA HOLDING A.S., 2:24-cv-04404, No. 57 (D.N.J. Feb. 21, 2025)

cite Cite Document
Analyze

No. 1

Document INCYTE CORPORATION et al v. SUN PHARMACEUTICAL INDUSTRIES LTD. et al, 2:24-cv-06944, No. 1 (D.N.J. Jun. 11, 2024)

cite Cite Document
Analyze

No. 56

Document TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. et al v. DEVA HOLDING A.S., 2:24-cv-04404, No. 56 (D.N.J. Feb. 11, 2025)

cite Cite Document
Analyze
<< 1 2 3 4 5 6 7 8 ... >>